Earlier this year, Caris Life Sciences added next-gen sequencing to its portfolio of tumor profiling services. The company has since sequenced thousands of patients using Illumina's TruSeq targeted cancer panel on the MiSeq and is developing its own customized 60-gene assay that it plans to launch in the first quarter of next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.